Hepatitis B core protein modulators

A compound represented by

• wherein
• Y is selected from the group consisting of S(O)y, C═O, C(R11)2, NRY and O wherein y is 0, 1, or 2;
• RY is selected from the group consisting of H, methyl, ethyl, propyl, proprene, butyl, phenyl and benzyl;
• RZ is selected from the group consisting of H, methyl, ethyl, propyl, phenyl and benzyl;
• Rm′ and Rm are each independently selected from the group consisting of H, C1-6alkyl optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl, and C2-6alkenyl optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl;
• Rc is selected from the group consisting of H, C1-6alkyl and C2-6alkenyl;
• R78 is selected from the group consisting of H, cyano, CHO, C1-6alkyl, carboxy, —C(O)—O—C1-6alkyl;
• —NR′R″;
• phenyl optionally substituted with one, two, three or four substituents each independently selected from the group consisting of R73;
• benzyl optionally substituted with one or more substituents each independently selected from the group consisting of R73, a saturated or partially unsaturated 4-7 membered ring structure containing one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, wherein the saturated or partially unsaturated 4-7 membered ring structure is optionally substituted with one or more substituents each independently selected from the group consisting of R73;
• 5-6 membered monocyclic heteroaryl containing one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, wherein the 5-6 membered monocyclic heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of R73;
• 9-10 membered bicyclic heteroaryl containing one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, wherein the 9-10 membered bicyclic heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of R73 and X2—C0-6alkylene-R79;
• X2 is selected from the group consisting of S(O)w (wherein w is 0,1, or 2), O, —C(O)— and NR′;
• R79 is selected from the group consisting of H, halogen, hydroxyl, nitro, cyano, CHO, C1-6alkyl, —C(O)—O—C1-6alkyl, —C(O)—NR′R″, —C(═NH)—NR′R″, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, carboxy, NR′R″, —C(O)—C1-6alkyl, C3-6cycloalkyl, —NR′—C(O)—C1-6alkyl, NR′—C(O)—O—C1-6alkyl, —S(O)w—C1-6alkyl (where w is 0, 1 or 2), —S(O)w—NR′R″ (where w is 0, 1 or 2), and —NR′—S(O)w—C1-6alkyl (where w is 0, 1 or 2);
• R73 is selected from the group consisting of H, halogen, hydroxyl, nitro, cyano, CHO, oxo, C1-6alkyl, —C(O)—O—C1-6alkyl, —C(O)—NR′—C1-6alkyl, —C(═NH)—NR′R″, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, carboxy, NR′R″, —C(O)—C1-6alkyl, —C3-6cycloalkyl, NR′—C(O)—C1-6alkyl, NR′—C(O)—O—C1-6alkyl, —S(O)w—C1-6alkyl (where w is 0, 1 or 2), —S(O)w—NR′R″ (where w is 0, 1 or 2), —NR′—S(O)w—C1-6alkyl (where w is 0, 1 or 2), C(O)—NR′—C1-6alkyl, C(O)—C1-3alkylene-NR′— C(O)—O—C1-6alkyl, and X2—C0-6alkylene-R79;
• R′ is selected, independently for each occurrence, from H, methyl, ethyl, cyclopropyl, cyclobutyl, and propyl;
• R″ is selected, independently for each occurrence, from H, methyl, ethyl, propyl optionally substituted by hydroxyl, butyl optionally substituted by hydroxyl, —C(O)-methyl and —C(O)-ethyl, or R′ and R″ taken together with the nitrogen to which they are attached may form a saturated or partially unsaturated 4-6 membered ring structure containing one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, wherein the saturated or partially unsaturated 4-6 membered ring structure is optionally substituted by one or more substituents selected from the group consisting of halogen, NH2, —C(O)—O—C1-6alkyl, —C(O)—C1-6alkyl, carboxy and C1-6alkyl;
• R11, for each occurrence, is selected from the group consisting of H, halogen, and C1-6alkyl optionally substituted with one, two, or three halogens;
• each of moieties R4, R5, R7, R8, R9, and R10 is independently selected for each occurrence from the group consisting of hydrogen, C1-6alkyl, C2-6alkynyl, C2-6alkenyl, halogen, hydroxyl, nitro, cyano, and NR′R″;
• and
• wherein for each occurrence, C1-6alkyl, C2-6alkenyl or C2-6alkynyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, C3-6cycloalkyl, C2-4alkenyl, C2-4alkynyl, C1-3alkoxy, NR′R″, —NR′—S(O)w—C1-2alkyl (where w is 0, 1 or 2), NR′—C(O)—C1-3alkyl, NR′—C(O)—O—C1-3alkyl, and S(O)w—NR′R″ (where w is 0, 1 or 2);
• C1-6alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C1-3alkyl, NR′R″, —NR′—S(O)w—C1-2alkyl (where w is 0, 1 or 2), and S(O)w—NR′R″;
• C1-6alkylene may be optionally substituted by a substituent selected from the group consisting of C3-6cycloalkyl, hydroxyl, cyano, and halogen;
• or a pharmaceutically acceptable salt thereof.